Lourdes Escoda, Tarragona, Spain
Tomás Ripoll-Vera, Palma de Mallorca, Spain
Organ Transplantation in Systemic Amyloidosis
Claudio Rapezzi, Bologna, Italy
Pablo García-Pavía, Madrid, Spain
Heart transplantation in AL amyloidosis
Arnt V. Kristen, Heidelberg, Germany
Heart transplantation in ATTR amyloidosis
Mathew Maurer, NY, USA
Liver transplantation in hereditary ATTR amyloidosis
Bo-Göran Ericzon, Huddinge, Sweden
Kidney transplant in AL amyloidosis and monoclonal immunoglobulin deposition disease: who and when?
Nelson Leung, Rochester, MN, USA
Multidisciplinary treatment approach in the management of patients with AL Amyloidosis
Giovanni Palladini, Pavia, Italy
Diagnostic pit-falls and risk stratification in AL amyloidosis
Efstathios Kastritis, Athens, Greece
Monoclonal antibody treatment for AL amyloidosis
Ashutosh Wechalekar, London, UK
Novel targets and drugs for AL amyloidosis
Giovanni Palladini, Pavia, Italy
International Kidney MG working Group
Experts’ Discussion on ASCT in AL amyloidosis: burning questions
Raymond Comenzo, Boston, MA, USA
Vaishali Sanchorawala, Boston, MA, USA
Heather Landau, New York, NY, USA
Hasib Sidiqi, Rochester,MN, USA
Carlos Fernández de Larrea, Barcelona, Spain
Eli Muchtar, Rochester, MN, USA
• Patient selection
• Decreasing transplant-related mortality
• Pretransplant induction
• ASCT in patients with renal function impairment
• Any role for consolidation or maintenance?
• Is it time for CAR-T cell therapy in AL amyloidosis?
Hereditary Transthyretin Amyloidosis
Ole Suhr, Umeå, Sweden
M. Teresa Cibeira, Barcelona, Spain
Multidisciplinary management and quality of life of patients with ATTR polyneuropathy
Teresa Coelho, Porto, Portugal
Potential predictors of response and progression to treatment of hereditary TTR amyloidosis
Violaine Plante-Bordeneuve, Créteil, France
Treatment of hereditary TTR amyloidosis with antisense agents
Carlos Casasnovas, Barcelona, Spain
Rodney H. Falk, Boston, MA, USA